Leukemia, Lymphocytic, Chronic, B Cell Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
E
Recruiting
  • Leukemia, Lymphoid
  • +6 more
  • Wuhu, Anhui, China
  • +21 more
2022-04-06
Apr 6, 2022
L
Available
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • +4 more
  • Stanford, California
  • +19 more
2022-04-05
Apr 5, 2022
J
Recruiting
  • Lymphoma, Non-Hodgkin
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Birmingham, Alabama
  • +34 more
2022-03-24
Mar 24, 2022
J
Active, not recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma, Mantle-Cell
  • Paris Cedex 13, France
    (unnamed)
2022-03-24
Mar 24, 2022
J
Recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma, Non-Hodgkin
  • New York, New York
  • +33 more
2022-03-24
Mar 24, 2022
J
Recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma, Non-Hodgkin
  • Duarte, California
  • +49 more
2022-03-24
Mar 24, 2022
J
Recruiting
  • Lymphoma, Non-Hodgkin
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • New York, New York
  • +15 more
2022-03-24
Mar 24, 2022
E
Recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • +6 more
  • Miami, Florida
  • +4 more
2022-03-07
Mar 7, 2022
A
Completed
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Innsbruck, Tirol, Austria
  • +6 more
2022-02-15
Feb 15, 2022
S
Not yet recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • JWCAR029 (Relmacabtagene Autoleucel)
  • Nanjing, Jiangsu, China
    Jiangsu Province Hospital
2022-02-17
Feb 17, 2022
J
Recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma, Mantle-Cell
  • Ibrutinib 420 mg
  • Ibrutinib 560 mg
  • Ahmedabad, India
  • +12 more
2022-02-24
Feb 24, 2022
B
Not yet recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma
  • Birmingham, Alabama
  • +24 more
2022-02-08
Feb 8, 2022
C
Active, not recruiting
  • Lymphoma
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Gilbert, Arizona
  • +53 more
2022-01-25
Jan 25, 2022
J
Recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma, Small Lymphocytic
  • JCAR017 (lisocabtagene maraleucel)
  • +2 more
  • Birmingham, Alabama
  • +33 more
2022-01-25
Jan 25, 2022
J
Completed
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Ancona, Italy
  • +38 more
2021-12-30
Dec 30, 2021
M
Completed
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • +2 more
  • Tafasitamab
  • +2 more
  • Jacksonville, Florida
  • +16 more
2021-12-10
Dec 10, 2021
U
Recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Abnormalities Cell Epithelial
    • Zurich, Switzerland
      University Hospital Zurich
    2021-10-05
    Oct 5, 2021
    M
    Terminated
    • Non-Hodgkin's B-cell Lymphoma
    • +5 more
    • MT-3724 Phase 1
    • MT-3724 Phase 2
    • Tucson, Arizona
    • +40 more
    2021-08-30
    Aug 30, 2021
    M
    Recruiting
    • Lymphoma, Non-Hodgkin
    • +4 more
      • Rochester, Minnesota
        Mayo Clinic
      2021-08-30
      Aug 30, 2021
      R
      Completed
      • Leukemia, Lymphocytic, Chronic, B-Cell
      • Pleven, Bulgaria
      • +5 more
      2021-07-22
      Jul 22, 2021
      C
      Recruiting
      • Leukemia
      • +4 more
      • CD19 CAR-T cells
      • Kunming, Yunnan, China
        920th Hospital of Joint Logistics Support Force
      2021-03-01
      Mar 1, 2021
      C
      Recruiting
      • Leukemia
      • +3 more
      • CD19 CAR-T cells
      • Chongqing, Chongqing, China
        Chongqing University Cancer Hospital
      2021-03-01
      Mar 1, 2021
      H
      Completed
      • Lymphoma, Non-Hodgkin
      • Leukemia, Lymphocytic, Chronic, B-Cell
      • Bucheon-si,, Korea, Republic of
      • +24 more
      2021-01-07
      Jan 7, 2021